Literature DB >> 12869471

Impact of DOTS and DOTS-plus on multidrug resistant TB: DOTS-plus strengthens, not weakens, DOTS programmes.

Edward A Nardell.   

Abstract

Mesh：

Year:  2003        PMID： 12869471      PMCID： PMC1126525          DOI： 10.1136/bmj.327.7407.164

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  Increasing transparency in partnerships for health--introducing the Green Light Committee.

Authors:  Rajesh Gupta; J Peter Cegielski; Marcos A Espinal; Myriam Henkens; Jim Y Kim; Catherina S B Lambregts-Van Weezenbeek; Jong-Wook Lee; Mario C Raviglione; Pedro G Suarez; Francis Varaine
Journal:  Trop Med Int Health       Date:  2002-11       Impact factor: 2.622

2.  Primary multidrug-resistant tuberculosis--Ivanovo Oblast, Russia, 1999.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1999-08-06       Impact factor: 17.586

3.  Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru.

Authors:  Carole Mitnick; Jaime Bayona; Eda Palacios; Sonya Shin; Jennifer Furin; Felix Alcántara; Epifanio Sánchez; Madeleny Sarria; Mercedes Becerra; Mary C Smith Fawzi; Saidi Kapiga; Donna Neuberg; James H Maguire; Jim Yong Kim; Paul Farmer
Journal:  N Engl J Med       Date:  2003-01-09       Impact factor: 91.245

4.  Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy.

Authors:  G B Migliori; M Espinal; I D Danilova; V V Punga; M Grzemska; M C Raviglione
Journal:  Int J Tuberc Lung Dis       Date:  2002-10       Impact factor: 2.373

5.  Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis.

Authors:  Timothy R Sterling; Harold P Lehmann; Thomas R Frieden
Journal:  BMJ       Date:  2003-03-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.